Omeprazole | indigestion and heartburn and acid reflux

OMLINK (Omeprazole 20mg)

OMLINK (Omeprazole 20mg)

Omeprazole inhibits the secretion of gastric acid by irreversibly blocking the enzyme system of H

+/K+ATPase of the gastric parietal cell.


Orally omeprazole is well absorbed from small intestine completely within 3-6 hours with 95% plasma proteins bound & T ½ is 30 to 90 minutes with total body clearance is 500-600mL/min. Inactive metabolites are excreted 80% in urine & 2% via faeces


Omeprazole is indicated for the treatment of Oesophageal reflux disease, dyspepsia, duodenal and benign gastric ulcers, ulcers related to Helicobacter pylori

, NSAID-associated benign gastric ulcers and gastroduodenal erosion in patients continued NSAID treatment. Prophylaxis of acid aspiration and Zollinger-Ellison syndrome.


In patients with history to Omeprazole or to any of excipients of this product.

Special precautions and warnings

  • Relief of symptoms does not preclude the presence of a gastric malignancy.
  • Use of Omeprazole capsules may increase risk of GI infection (e.g. Salmonella, Campylobacter).
  • Bioavailability of Omeprazole may be increased in patients with hepatic dysfunction; consider dosage reductions, especially for maintenance healing of erosive esophagitis.
  • Use during pregnancy & lactation, if potential benefit to mother outweighs possible risk to fetus.

Dosage and directions for use

Duodenal ulcer: 20mg once daily for two to four weeks

Prevention of relapse of duodenal ulcer: 10mg/daily, can be increased to 20-40mg/day

Gastric ulcer and reflux oesophagitis: 20-40 mg once daily for four to eight weeks

NSAID-associated gastric and duodenal ulcers: 20mg once daily

Symptomatic gastroesophageal reflux disease: 10 to 20mg daily

Zollinger-Ellison syndrome: 60mg once daily

H.pylori eradication for duodenal ulcer recurrence: 20mg with antibiotics as a triple therapy.

Pediatric patients

For GERD & to maintain erosive esophagitis healing, 5mg/day for 5<10kg, 10mg/day for 10<20 kg, 20mg/day for >20kg

Dosage should be adjusted individually & treatment continued as long as clinically indicated.

Adverse effects

Commonly observed adverse events are headache, abdominal pain, nausea, constipation, diarrhoea, flatulence, nausea/vomiting. Other adverse effects are acid regurgitation, upper respiratory infection, constipation, dizziness, rash, asthenia, back-pain and cough.

Drug interactions

Reduced absorption of ketoconazole or itraconazole with omeprazole treatment. Omeprazole may increase serum concentration of tacrolimus, Vitamin K antagonists and benzodiazepines. Increase in digoxin bioavailability with omeprazole. Omeprazole may decrease the serum concentration of Atazanavir. Concomitant administration of Omeprazole & CYP2C19 and CYP3A4 inhibitor, voriconazole resulted in doubling of omeprazole exposure


Leave a Reply

%d bloggers like this: